• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在患有VIII因子抑制剂的甲型血友病患者接受重组VII因子a治疗期间,血栓弹力图作为一种止血监测手段。

Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.

作者信息

Yoshioka A, Nishio K, Shima M

机构信息

Department of Pediatrics, Nara Medical University, Japan.

出版信息

Haemostasis. 1996;26 Suppl 1:139-42. doi: 10.1159/000217256.

DOI:10.1159/000217256
PMID:8904189
Abstract

Thrombelastgram (TEG) is an old but automated instrument that demonstrates changes occurring during blood coagulation and fibrinolysis. TEG was evaluated to be better than activated partial thromboplastin time (APTT) as a monitor of hemostatic effects when using recombinant factor VIIa (65-80 mu g/kg) in 3 hemophilia A patients with a high titer of factor VIII inhibitors. TEG was more suitable than APTT, because r, r + k and ma values of TEG were normalized at least for 4 h after the infusion, whereas APTT was variably shortened and was not always maintained at a normal level for 4 h.

摘要

血栓弹力图(TEG)是一种虽旧但自动化的仪器,可显示血液凝固和纤维蛋白溶解过程中发生的变化。在3例高滴度因子VIII抑制剂的甲型血友病患者中,当使用重组因子VIIa(65 - 80μg/kg)时,血栓弹力图被评估为比活化部分凝血活酶时间(APTT)更适合作为止血效果的监测指标。血栓弹力图比APTT更合适,因为输注后血栓弹力图的r、r + k和ma值至少在4小时内恢复正常,而APTT则不同程度缩短,且并非总能在4小时内维持在正常水平。

相似文献

1
Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.在患有VIII因子抑制剂的甲型血友病患者接受重组VII因子a治疗期间,血栓弹力图作为一种止血监测手段。
Haemostasis. 1996;26 Suppl 1:139-42. doi: 10.1159/000217256.
2
Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.评估和监测重组活化凝血因子VIIa在血友病及抑制物患者中的疗效。
Blood Coagul Fibrinolysis. 2014 Oct;25(7):754-60. doi: 10.1097/MBC.0000000000000137.
3
Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor.血栓弹力图引导下的VIIa因子治疗在一名患有严重血友病和VIII因子抑制剂的外科手术患者中的应用
Anesth Analg. 2008 Aug;107(2):398-401. doi: 10.1213/ane.0b013e31817b7864.
4
Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.凝血因子VIIa类似物对甲型血友病患者血液中的血小板功能和凝血动力学有显著影响。
Blood Coagul Fibrinolysis. 2010 Sep;21(6):539-46. doi: 10.1097/MBC.0b013e32833b63e9.
5
Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.采用旋转血栓弹性描记术对伴有抑制剂的血友病 A 患者围手术期的止血管理进行系统监测。
J Thromb Haemost. 2015 Jul;13(7):1279-84. doi: 10.1111/jth.12987. Epub 2015 May 29.
6
Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity.重组凝血因子VIIa在一名甲型血友病且对凝血因子VIII抑制物旁路活性无反应的高滴度抑制物患者紧急筋膜切开术中的成功应用。
Am J Hematol. 2005 May;79(1):58-60. doi: 10.1002/ajh.20314.
7
Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review.在一名患有血友病且对凝血因子 VIII 有高滴度抑制物的儿童中,使用血栓弹力图监测进行重组凝血因子 VIIa 的剂量滴定:病例报告及简要综述
J Extra Corpor Technol. 2006 Sep;38(3):254-9.
8
Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII.重组凝血因子VIIa对VIII因子抑制患者止血功能的控制
Lancet. 1991 Sep 28;338(8770):831-2. doi: 10.1016/0140-6736(91)90729-9.
9
Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots.评价重组凝血因子 VIIa 的总体止血效果,通过测量凝血酶生成和纤维蛋白凝块的稳定性。
Haemophilia. 2011 Nov;17(6):957-61. doi: 10.1111/j.1365-2516.2011.02526.x. Epub 2011 Apr 1.
10
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.抗凝血 IX 处理的血液和血浆中凝血酶生成和纤维蛋白溶解,加入 VIII 因子抑制物旁路活性或重组 VIIa 因子。
Haemophilia. 2010 May;16(3):510-7. doi: 10.1111/j.1365-2516.2009.02164.x. Epub 2009 Dec 29.

引用本文的文献

1
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.支持重组活化凝血因子 VII 用于先天性出血性疾病的证据。
Drug Des Devel Ther. 2010 Jul 21;4:107-16. doi: 10.2147/dddt.s11764.